Noa Eliakim-Raz1,2, Tanya Babitch1,2, Evelyn Shaw3,4, Ibironke Addy5, Irith Wiegand5, Christiane Vank5, Laura Torre-Vallejo6, Vigo Joan-Miquel7, Morris Steve6, Sally Grier8, Margaret Stoddart8, Cuperus Nienke9, van den Heuvel Leo9, Cuong Vuong5, Alasdair MacGowan8, Jordi Carratalà3,4, Leonard Leibovici1,2, Miquel Pujol3,4. 1. Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva. 2. Sackler Faculty of Medicine, Tel-Aviv University, Israel. 3. Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Català de la Salut, Bellvitge Biomedical Research Institute, University of Barcelona. 4. Spanish Network for Research in Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain. 5. AiCuris Anti-infective Cures GmbH, Wuppertal, Germany. 6. Department of Applied Health Research, University College London, United Kingdom. 7. Informatics Unit, Fundació Institut Català de Farmacologia, Barcelona, Spain. 8. Department of Medical Microbiology, Southmead Hospital, North Bristol National Health Services Trust, United Kingdom. 9. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.
Abstract
Background: Complicated urinary tract infections (cUTIs) are responsible for a major share of all antibiotic consumption in hospitals. We aim to describe risk factors for treatment failure and mortality among patients with cUTIs. Methods: A multinational, multicentre retrospective cohort study, conducted in 20 countries in Europe and the Middle East. Data were collected from patients' files on hospitalised patients with a diagnosis of cUTI during 2013-2014. Primary outcome was treatment failure, secondary outcomes included 30 days all-cause mortality,among other outcomes. Multivariable analysis using a logistic model and the hospital as a random variable was performed to identify independent predictors for these outcomes. Results: A total of 981 patients with cUTI were included. Treatment failure was observed in 26.6% (261/981), all cause 30-day mortality rate was 8.7% (85/976), most of these in patients with catheter related UTI (CaUTI). Risk factors for treatment failure in multivariable analysis were ICU admission (OR 5.07, 95% CI 3.18-8.07), septic shock (OR 1.92, 95% CI 0.93-3.98), corticosteroid treatment (OR 1.92, 95% CI 1.12-3.54), bedridden (OR 2.11, 95%CI 1.4-3.18), older age (OR 1.02, 95% CI 1.0071.03-), metastatic cancer (OR 2.89, 95% CI 1.46-5.73) and CaUTI (OR 1.48, 95% CI 1.04-2.11). Management variables, such as inappropriate empirical antibiotic treatment or days to starting antibiotics were not associated with treatment failure or 30-day mortality. More patients with pyelonephritis were given appropriate empirical antibiotic therapy than other CaUTI [110/171; 64.3% vs. 116/270; 43%, p <0.005], nevertheless, this afforded no advantage in treatment failure rates nor mortality in these patients. Conclusions: In patients with cUTI we found no benefit of early appropriate empirical treatment on survival rates or other outcomes. Physicians might consider supportive treatment and watchful waiting in stable patients until the causative pathogen is defined.
Background: Complicated urinary tract infections (cUTIs) are responsible for a major share of all antibiotic consumption in hospitals. We aim to describe risk factors for treatment failure and mortality among patients with cUTIs. Methods: A multinational, multicentre retrospective cohort study, conducted in 20 countries in Europe and the Middle East. Data were collected from patients' files on hospitalised patients with a diagnosis of cUTI during 2013-2014. Primary outcome was treatment failure, secondary outcomes included 30 days all-cause mortality,among other outcomes. Multivariable analysis using a logistic model and the hospital as a random variable was performed to identify independent predictors for these outcomes. Results: A total of 981 patients with cUTI were included. Treatment failure was observed in 26.6% (261/981), all cause 30-day mortality rate was 8.7% (85/976), most of these in patients with catheter related UTI (CaUTI). Risk factors for treatment failure in multivariable analysis were ICU admission (OR 5.07, 95% CI 3.18-8.07), septic shock (OR 1.92, 95% CI 0.93-3.98), corticosteroid treatment (OR 1.92, 95% CI 1.12-3.54), bedridden (OR 2.11, 95%CI 1.4-3.18), older age (OR 1.02, 95% CI 1.0071.03-), metastatic cancer (OR 2.89, 95% CI 1.46-5.73) and CaUTI (OR 1.48, 95% CI 1.04-2.11). Management variables, such as inappropriate empirical antibiotic treatment or days to starting antibiotics were not associated with treatment failure or 30-day mortality. More patients with pyelonephritis were given appropriate empirical antibiotic therapy than other CaUTI [110/171; 64.3% vs. 116/270; 43%, p <0.005], nevertheless, this afforded no advantage in treatment failure rates nor mortality in these patients. Conclusions: In patients with cUTI we found no benefit of early appropriate empirical treatment on survival rates or other outcomes. Physicians might consider supportive treatment and watchful waiting in stable patients until the causative pathogen is defined.
Authors: Sara Grillo; Guillermo Cuervo; Jordi Carratalà; Immaculada Grau; Mariona Llaberia; José María Aguado; Luis Eduardo Lopez-Cortés; Antonio Lalueza; Rafael Sanjuan; Ana Sanchez-Batanero; Carmen Ardanuy; Dolors García-Somoza; Cristian Tebé; Miquel Pujol Journal: Open Forum Infect Dis Date: 2020-06-06 Impact factor: 3.835
Authors: Aina Gomila; J Carratalà; N Eliakim-Raz; E Shaw; I Wiegand; L Vallejo-Torres; A Gorostiza; J M Vigo; S Morris; M Stoddart; S Grier; C Vank; N Cuperus; L Van den Heuvel; C Vuong; A MacGowan; L Leibovici; I Addy; M Pujol Journal: Infect Drug Resist Date: 2018-12-18 Impact factor: 4.003
Authors: Domingo Palacios-Ceña; Lidiane Lima Florencio; Valentín Hernández-Barrera; Cesar Fernandez-de-Las-Peñas; Javier de Miguel-Diez; David Martínez-Hernández; David Carabantes-Alarcón; Rodrigo Jimenez-García; Ana Lopez-de-Andres; Marta Lopez-Herranz Journal: J Clin Med Date: 2021-05-26 Impact factor: 4.241
Authors: Victor Garcia-Bustos; Ana Isabel Renau Escrig; Cristina Campo López; Rosario Alonso Estellés; Koen Jerusalem; Marta Dafne Cabañero-Navalón; Victoria Morell Massó; Ignacio-Antonio Sigona-Giangreco; José Miguel Sahuquillo-Arce; Iván Castro Hernández; Miguel Salavert Lletí Journal: Sci Rep Date: 2021-06-07 Impact factor: 4.379
Authors: Aina Gomila; Evelyn Shaw; Jordi Carratalà; Leonard Leibovici; Cristian Tebé; Irith Wiegand; Laura Vallejo-Torres; Joan M Vigo; Stephen Morris; Margaret Stoddart; Sally Grier; Christiane Vank; Nienke Cuperus; Leonard Van den Heuvel; Noa Eliakim-Raz; Cuong Vuong; Alasdair MacGowan; Ibironke Addy; Miquel Pujol Journal: Antimicrob Resist Infect Control Date: 2018-09-14 Impact factor: 4.887